Hypomethylating Agents Development Services

Epigenetic modification, namely DNA methylation, is an important therapeutic target for hematopoietic malignant tumors. Alfa Cytology provides drug development services for DNA methylation, focusing on integrated services for low-methylation drugs (HMA). We are dedicated to advancing leukemia research and offering innovative solutions for therapy of various hematological malignancies.

Introduction to Hypomethylating Agents for Leukemia

Relapsed and refractory AML pose significant challenges in clinical practice, necessitating novel therapeutic strategies. HMA, including chemotherapy drug and decitabine, have dependent epigenetic and cytotoxic effects and have emerged as promising therapeutic options for these people. These agents exert their anti-leukemic effects by reversing DNA methylation, reactivating tumor suppressor genes, and inducing the re-programming of leukemic cells.

Fig. 1. Schematic representation of chemotherapy drug and decitabine uptake and metabolism. (Stomper, J. et al., 2021)

Our Services

Hypomethylating agents are drugs that inhibit DNA methylation, which is an epigenetic therapy. Alfa Cytology provides comprehensive hypomethylating agent development services, including but not limited to the following.

Discovery of Hypomethylating Agents

The structure of hypomethylating agents was compared with the DrugBank database by the SS method, which contained more than 1,000 compounds approved at the time of the study. Molecular modeling and chemical informatics methods were employed to develop novel hypomethylating agents as potential therapeutics for acute myeloid leukemia.
New drugs can be obtained by drug molecular design or chemical modification of Decitabine to improve the stability of drugs and prolong the half-life of drugs.
Mutations involving methylation genes are associated with the therapy and pathogenesis of leukemia. We can design and develop new targeted drugs based on DNA-methylated genes DNMT3A, TET2, and IDH1/IDH2.

Targets for Hypomethylating Agents

DNA Methyltransferase (DNMT)

DNMT has been identified as a therapeutic target and modulator of drug resistance in leukemia. We offer drug development services targeting this specific target.

Ten-eleven Translocation (TET)

TET inhibitors may represent a novel class of targeted drugs for TET2-mutant tumors. We can assist you in exploring the development of TET inhibitors.

Development of Potential Combination Therapies

Hypomethylating Agents and Other Inhibitors

Hypomethylating agents combined with histone deacetylase inhibitors (HDAC) can enhance the therapeutic effect on leukemia. Our assistance includes exploring the development of this combination. We can help you explore the development of a combination of hypomethylating agents and HDAC, and study their potential synergies and therapeutic effects on leukemia models.

Hypomethylating Agents and Histone Deacetylase Inhibitors

We offer the development of combination therapy using hypomethylating agents, BCL-2 inhibitors, and FLT3 inhibitors, as well as chemotherapeutic drugs, to explore the effects of different combinations of drugs. Our professional services will help you find new therapy directions and provide solutions for refractory and recurrent AML or drug resistance.

Advantages of Our Services

A fast and efficient experimental process.
Accurate verification process.
A full range of drug development services.
Development of combined therapy for hypomethylating agents.

Alfa Cytology's dedicated services for hypomethylating agents in relapsed and refractory AML aims to accelerate the development of effective therapeutics for individuals facing limited therapeutic choices. By leveraging our expertise, infrastructure, and collaborative approach, we strive to make significant contributions to the field of AML research and ultimately improve outcomes. Contact us to discuss your specific needs and how our services can support your drug development.

Reference

Stomper, J.; et al. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021. 35(7): 1873-1889.

For research use only. Not intended for any clinical use.